Unsaturated algin trisaccharide ursolic acid ester as well as preparation method and application thereof
Through the esterification reaction of unsaturated alginate trisaccharide urfate, the skin thinning and drug resistance problems of existing eczema treatment drugs have been solved, and the skin barrier repair and long-term anti-inflammatory effect is achieved. It is suitable for eczema prevention and treatment.
Patent Information
- Application Number
- CN202411036142.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-15
AI Technical Summary
Existing eczema treatment drugs have problems such as skin thinning, infection risk, drug resistance and side effects after long-term use, and lack effective immune regulation and skin barrier repair components.
Unsaturated alginate trisaccharide urfate is used to improve the performance of urfate through esterification reaction, forming compounds with excellent immunomodulation and moisture-absorbing and moisturizing activities. It is used to prepare skin dressings and skin care products, repair skin barriers and reduce inflammation .
Unsaturated brown algae trisaccharide urfate can keep the skin moist for a long time, reduce inflammation, significantly improve skin damage caused by eczema, have good anti-inflammatory and immune regulation effects, and are suitable for long-term use.
Smart Images

Figure CN118955750A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of preventing and treating eczematous skin diseases, and in particular to unsaturated alginate trisaccharide ursolic acid ester and a preparation method and application thereof. Background Art
[0002] Eczema is a common inflammatory skin disease of the epidermis and superficial dermis caused by a variety of internal and external factors. It is generally believed to be related to allergic reactions. Its clinical manifestations are characterized by symmetry, exudation, itching, polymorphism and recurrence. Eczema is also an allergic inflammatory skin disease, characterized by diverse rashes, symmetrical distribution, repeated attacks of severe itching, and easy development into a chronic disease. In recent years, its prevalence has remained high. The cause of eczema is quite complex and has not yet been fully explained. The traditional view is that it is mainly caused by hypersensitivity reactions. Numerous inflammatory cells and cytokines participate in the pathogenesis of eczema through the immune regulatory network system or signal pathway conduction.
[0003] Among the current clinical treatment methods for eczema, anti-infective drugs, hormone drugs, and anti-allergic drugs are generally available for treatment. Hormones include mometasone furoate cream, triamcinolone acetonide, dexamethasone and other drugs. If secondary infection occurs, anti-infective drugs such as miconazole clobetasol and azithromycin can be added. If itching seriously affects sleep, anti-allergic drugs such as loratadine and cetirizine can be selected. These drugs are not easy to use for a long time. Long-term use of hormone drugs can make the skin thin and easy to be injured. The skin has uncomfortable symptoms such as bruises, redness, swelling, and itching, which in turn cause skin infections or viral infections. Long-term use of antibiotics can also produce adverse reactions such as drug resistance. Long-term use of anti-allergic drugs may cause symptoms of drowsiness and fatigue. Therefore, there is an urgent need for drugs for the treatment of eczema with better effects and better side effects.
[0004] Ursolic acid is a triterpenoid compound, which is distributed in about 7 families, 46 genera and 62 species of plants in free form or in the form of glycosides combined with sugars. Animal experimental studies have shown that ursolic acid improves DNCB-induced atopic dermatitis-like symptoms in mice by regulating the TLR4 / NF-κB and Nrf2 / HO-1 signaling pathways. However, ursolic acid has poor hygroscopic and moisturizing activity and cannot form a protective film on the skin surface to maintain the moisture of the skin. Our previous studies have found that unsaturated alginate trisaccharide ursolic acid ester has good immunomodulatory activity, can fit the skin well, maintain the moist environment of the skin, and effectively repair the skin barrier, making it suitable for long-term use. Summary of the invention
[0005] In order to solve the above technical problems, the present invention provides an unsaturated alginate trisaccharide ursolic acid ester and a preparation method and application thereof, so as to achieve the purpose of effectively repairing the skin barrier and protecting and repairing skin damage caused by eczema from multiple pathways.
[0006] To achieve the above object, the technical solution of the present invention is as follows:
[0007] An unsaturated alginate trisaccharide ursolic acid ester, the structural formula of which is as follows:
[0008]
[0009] Among them, R1, R2, R3, R4, R5, R6 are C 30 H 47 O2 or H, and at least one of them is C 30 H 47 O2.
[0010] A method for preparing the unsaturated alginate trisaccharide ursolic acid ester as described above comprises the following steps: dissolving the unsaturated alginate trisaccharide in N,N-dimethylformamide, sequentially adding N,N'-carbonyldiimidazole and 4-dimethylaminopyridine, stirring at room temperature under nitrogen protection; then adding ursolic acid, continuing the reaction at room temperature, and concentrating under reduced pressure to remove the solvent after the reaction is completed, dissolving in water, extracting with dichloromethane, concentrating the aqueous phase, and freeze-drying to obtain the unsaturated alginate trisaccharide ursolic acid ester.
[0011] In the above scheme, the unsaturated alginate trisaccharide is an alginate oligosaccharide with a degree of polymerization of 3, which is obtained by connecting unsaturated mannuronic acid, mannuronic acid and guluronic acid in a 1-4 manner.
[0012] In the above scheme, the preparation method of the unsaturated alginate trisaccharide is as follows:
[0013] Weigh 20g of sodium alginate and dissolve it in deionized water to make the gel solution concentration 2%, mechanically stir it to make it a uniform system, add alginate lyase, the mass concentration of alginate lyase in sodium alginate is 0.5%, and enzymolysis is carried out at 45℃ for 24h; after the enzymolysis is completed, heat to 100℃, react for 10min, centrifuge, concentrate and freeze-dry the enzymolysis solution to obtain unsaturated alginate oligosaccharides;
[0014] Unsaturated alginate oligosaccharides were purified using Bio-gel P4 gel column with 0.5M NH4HCO3 as eluent. The effluent was automatically collected, 0.5 mL per tube, and the degree of polymerization of oligosaccharides was determined by ESI-MS. The unsaturated alginate oligosaccharides with a degree of polymerization of 3 were desalted and freeze-dried to obtain unsaturated alginate trisaccharides.
[0015] In the above scheme, the preparation method of unsaturated alginate trisaccharide ursolic acid ester is as follows: 2 g of unsaturated alginate trisaccharide is dissolved in 10-40 mL of N,N-dimethylformamide, and 2-4 g of N,N'-carbonyldiimidazole and 0.5-2.1 g of 4-dimethylaminopyridine are added in sequence, and stirred at room temperature for 20-70 min under nitrogen protection; 1-3.5 g of ursolic acid is added, and the reaction is continued at room temperature for 4-15 h. After the reaction is completed, the solvent is removed by concentration under reduced pressure, 30-100 mL of water is added to dissolve, and then extracted with 30-60 mL of dichloromethane, and the process is repeated 2-5 times; the aqueous phase is concentrated and freeze-dried to obtain unsaturated alginate trisaccharide ursolic acid ester.
[0016] In the above scheme, the substitution degree of ursolic acid is 5-25%.
[0017] A use of the unsaturated alginate trisaccharide ursolic acid ester as described above in the preparation of medical dressings or skin care products for preventing and relieving skin eczema.
[0018] In a further technical solution, the unsaturated alginate trisaccharide ursolic acid ester is added as an active ingredient in a mass fraction of 0.5-5% in the preparation of medical dressings or skin care products for preventing and relieving skin eczema.
[0019] Through the above technical scheme, the alginate oligosaccharide used in the present invention is an acidic polysaccharide derived from brown algae, mainly composed of mannuronic acid and / or guluronic acid, and has multiple biological activities such as anti-oxidation, anti-virus, anti-tumor, and neuroprotection. Previous studies have found that the unsaturated alginate trisaccharide obtained by separating and purifying alginate oligosaccharides has good immunomodulatory activity. The present invention esterifies unsaturated alginate trisaccharide with ursolic acid to prepare unsaturated alginate trisaccharide ursolic acid ester.
[0020] The unsaturated alginate trisaccharide ursolic acid ester prepared by the present invention further improves the performance of ursolic acid. On the one hand, it has excellent immunoregulatory activity, can improve the imbalance of helper T cell (Th) 1 / Th2 cytokine secretion, and maintain the dynamic balance of immunity; on the other hand, the unsaturated alginate trisaccharide ursolic acid ester can form an invisible film, fit the skin well, maintain the moist environment of the skin, effectively repair the skin barrier, protect and repair the skin damage caused by eczema from multiple pathways, and has good application potential in the fields of drugs for preventing and treating eczema, medical dressings and cosmetics.
[0021] Compared with the prior art, the present invention has the following advantages:
[0022] 1. The unsaturated alginate trisaccharide ursolic acid ester prepared by the present invention has excellent moisture absorption and moisturizing, immunomodulation and skin barrier repair activities, can maintain the moist environment of the skin for a long time, and exert a long-term anti-inflammatory effect;
[0023] 2. The unsaturated alginate trisaccharide ursolic acid ester prepared by the present invention has hydrophilicity and lipophilicity, can better penetrate and stay in the dermis of the skin, effectively reduce skin inflammation, and better repair the skin barrier.
[0024] 3. The preparation method of the present invention is simple, the experimental materials are easily available, and it is convenient for mass preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.
[0026] Figure 1 This is the ESI-MS analysis diagram of △MMG.
[0027] Figure 2 This is the HPLC spectrum of △MMG.
[0028] Figure 3 For △MMG 1 H NMR spectrum.
[0029] Figure 4 For △MU 1 H NMR spectrum.
[0030] Figure 5 This is a comparison chart of the proliferation effects of △MU and ursolic acid on HaCaT cells.
[0031] Figure 6 This is a comparison chart of the hemolysis test results of △MU and ursolic acid.
[0032] Figure 7 The figures are a comparison of the moisturizing properties of △MU and ursolic acid; (a) is the moisturizing property under the condition of relative humidity of 80%; (b) is the moisturizing property under the condition of relative humidity of 50%.
[0033] Figure 8 The hygroscopicity comparison diagram of △MU and ursolic acid; (a) is the hygroscopicity under the condition of relative humidity of 81%, and (b) is the hygroscopicity under the condition of relative humidity of 42%.
[0034] Fig. 9 This is a comparison chart of the effects of △MU on inflammatory factors. DETAILED DESCRIPTION
[0035] The technical solutions in the embodiments of the present invention will be described clearly and completely below in conjunction with the accompanying drawings in the embodiments of the present invention.
[0036] The present invention provides an unsaturated alginate trisaccharide ursolic acid ester and a preparation method and application thereof, and specific embodiments are as follows:
[0037] 1. Preparation of unsaturated alginate trisaccharide (△MMG)
[0038] Weigh 20.0g of sodium alginate and dissolve it in deionized water to make the gel solution concentration 2.0%, stir it mechanically to make it a uniform system, add 0.5% alginate lyase, and enzymolyze it at 45℃ for 24h. After the enzymolysis is completed, heat it to 100℃ and react for 10min. The enzymolysis solution is centrifuged, concentrated, and freeze-dried to obtain unsaturated alginate oligosaccharide AOS.
[0039] Unsaturated alginate oligosaccharide AOS was purified by Bio-gel P4 gel column with 0.5M NH4HCO3 as eluent. The effluent was automatically collected, 0.5 mL in each tube, and the degree of polymerization of oligosaccharides was determined by electrospray ionization mass spectrometry (ESI-MS). The unsaturated alginate oligosaccharide with a degree of polymerization of 3 was desalted and freeze-dried to obtain unsaturated alginate trisaccharide.
[0040] 2. Structural characterization of unsaturated alginate trisaccharide (△MMG)
[0041] ESI-MS analysis Figure 1 As shown, G represents guluronic acid, M represents mannuronic acid, and from the charge-to-mass ratio of 527.09 and 263.04, it can be seen that the molecular weight of △MMG is 528, which is a trisaccharide containing an unsaturated bond.
[0042] The G / M ratio was determined by HPLC to determine its purity. 1 H NMR finally confirmed the sequence of single degree of polymerization oligosaccharide. The HPLC spectrum of unsaturated alginate trisaccharide is shown in Figure 2 As shown, combined with the standard monosaccharide spectrum, it can be seen that the molar ratio of M to G in unsaturated alginate trisaccharide is 2:1. It is also a trisaccharide, so the trisaccharide is composed of two M and one G, and the reducing end is an unsaturated bond. In order to distinguish it from the saturated bond, it is marked with △ before the arrangement, so the arrangement can be △MMG, △GMM, and △MGM. Calculated by the HPLC monosaccharide peak area, it can be known that the purity of unsaturated alginate trisaccharide is >99%.
[0043] 1H NMR of unsaturated alginate trisaccharide Figure 3 As shown in the literature, when the reducing end is guluronic acid, it is a double peak at 4.7-4.8 ppm; when the reducing end is mannuronic acid, it is a single peak at 4.7-4.8 ppm. 1 The H NMR spectrum shows a double peak at 4.7-4.8 ppm, so the terminal is guluronic acid, so the final structure is △MMG, and the molecular formula is C 18 H 24 O 18 , the molar molecular weight is 528.37, and the structure is shown below:
[0044]
[0045] 3. Preparation of unsaturated alginate trisaccharide ursolic acid ester (△MU)
[0046] Take 2g of △MMG and dissolve it in 25mL of N,N-dimethylformamide, then add 2.3g of N,N'-carbonyldiimidazole (CDI) and 1.7g of 4-dimethylaminopyridine (DMAP) in turn, and stir at room temperature for 30min under nitrogen protection. Add ursolic acid (C 30 H 48 O3, molar molecular weight is 456.70) 3.2g, continue to react at room temperature for 6h, after the reaction is completed, concentrate under reduced pressure to remove the solvent, add 10mL water to dissolve, extract with 10mL×3 dichloromethane, concentrate the aqueous phase to a small volume and freeze-dry, which is △MU. Its synthesis route is shown in the following formula.
[0047]
[0048] Among them, R1, R2, R3, R4, R5, R6 are C 30 H 47 O2 or H, and at least one of them is C 30 H 47 O2.
[0049] The substitution degree of ursolic acid is 11.2%. 1 H NMR spectrum Figure 4 As shown, △MU has a miscellaneous peak between 4.0-4.5ppm compared with △MMG, and 4.0-4.5ppm is the chemical shift of trisaccharide hydrogen connected to oxygen on the ester group, while 5.8ppm is the chemical shift of double bond hydrogen of ursolic acid, and 2.6-2.9ppm is the chemical shift of methyl group of ursolic acid.
[0050] 4. Test of the survival rate of HaCaT cells with unsaturated alginate trisaccharide ursolic acid ester (△MU)
[0051] Normally growing HaCaT cells were digested with trypsin and prepared into a cell suspension with complete culture medium at a concentration of 4 × 10 4 -5×10 4 / mL was inoculated in a 96-well plate and cultured for 4-6h to allow the cells to adhere to the wall. The control group (Control) continued to culture with complete medium, and the experimental group used △MU and ursolic acid, and the final concentrations were 100μg / mL, 200μg / mL, and 400μg / mL prepared with complete medium. After culturing in a 37℃ incubator for 24h, MTT (thiazolyl blue) was added and incubated for 4h. After aspirating the supernatant, 150μDMSO (dimethyl sulfoxide) was added to each well, and the absorbance was measured at 490nm by a microplate reader after thorough mixing to compare the cell survival rate.
[0052] Results Figure 5 The experimental results showed that △MU had no cytotoxicity to HaCaT cells, and could significantly promote the proliferation of HaCaT cells compared with the control group, and could promote the repair of the skin barrier.
[0053] 5. Hemolytic effect of unsaturated alginate trisaccharide ursolic acid ester (△MU) on blood cells
[0054] Take fresh blood from rats and remove fibrinogen to make a 2% red blood cell suspension. Add 2.5mL of the prepared red blood cell suspension to each test tube, then add 2.5mL of deionized water to the positive control group, 2.5mL of normal saline to the negative control group, and 2.5mL of △MU solution with a concentration of 100μg / Ml, 200μg / mL, 400μg / mL and ursolic acid solution of the same concentration to the experimental group. Incubate at 37℃ and observe the hemolysis of each group. After 3h, centrifuge at 1000r / min for 5min, take the supernatant and use an enzyme marker to measure the absorbance at 545nm to calculate the hemolysis rate.
[0055] Hemolysis rate (%) = (absorbance value of experimental group - absorbance value of negative control) / (absorbance value of positive control - absorbance value of negative control) × 100%.
[0056] The results of the hemolysis test are shown in Figure 6 The experimental results show that the hemolysis rate of △MU in all tested samples at different concentrations is extremely low, which meets the national standards.
[0057] 6. Moisture retention and moisture absorption experiment of unsaturated alginate trisaccharide ursolic acid ester (△MU)
[0058] Moisture retention: Prepare 10 mg / mL △MU and ursolic acid solutions respectively, place them in a constant temperature and humidity desiccator, and place them at room temperature under different humidity conditions (high humidity is 80%, low humidity is 50%), with 3 parallels in each group, and use 10 mg / mL sodium hyaluronate as the positive control. Weigh at intervals of 12 hours to calculate the moisture retention.
[0059] Moisture retention (g / g) = sample weight at time t / initial sample weight.
[0060] Hygroscopicity: Take 0.1g of △MU and ursolic acid dried to constant weight and place them in a constant temperature and humidity desiccator. At room temperature, high humidity (81%) and low humidity (42%), measure their hygroscopic activity. Each group has 3 parallels. Take 0.1g of sodium hyaluronate dried to constant weight as the positive control. Weigh them every 12 hours and calculate the hygroscopicity.
[0061] Hygroscopicity (g / g) = sample weight at time t / initial sample weight.
[0062] Results: The moisturizing property of △MU is shown in Figure 7 It can be seen that the moisturizing properties of △MU under high humidity (80%) and low humidity (50%) conditions are significantly better than those of the positive controls sodium hyaluronate and ursolic acid, indicating that it has good moisturizing properties. Figure 8 It can be seen that the hygroscopicity of △MU under high humidity (81%) and low humidity (42%) conditions is significantly better than that of the positive control sodium hyaluronate and ursolic acid. According to the results of the hygroscopic and moisturizing experiments, it can be concluded that △MU has better hygroscopic and moisturizing activity.
[0063] 7. Anti-inflammatory activity of unsaturated alginate trisaccharide ursolic acid ester (△MU)
[0064] Wild-type AB zebrafish were raised in 28°C fish water (water quality: 200 mg instant sea salt was added to 1 L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / LCaCO3). 2dpf wild-type AB zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). △MU and ursolic acid (250 μg / mL), positive control dexamethasone (3.92 μg / mL) were given respectively, and a normal control group and a model control group were set up at the same time, with a capacity of 3 mL per well. Except for the normal control group, the rest of the experimental groups were given sodium dodecyl sulfate (final concentration of 60 μg / ml) in water to establish a zebrafish skin inflammation model. Three experiments were set up in parallel. After treatment at 28°C for 16 h, the total RNA of each group of zebrafish was extracted using UniversalRNA Extraction TL Kit C, and the concentration and purity of the total RNA were determined using a UV-visible spectrophotometer. 2.00 μg of total RNA from zebrafish samples was taken to detect the expression of β-actin, IL-17, TNF-, IL-1, IL-10, IL-4, and IL-13 genes by q-PCR.
[0065] Results: The experimental results of zebrafish inflammation model are shown in Fig. 9 , 250g / mL △MU can reduce the mRNA expression of pro-inflammatory factors IL-17, TNF-a, and IL-1, and increase the mRNA expression of anti-inflammatory factors IL-10, IL-4, and IL-13. Therefore, △MU has a significant anti-inflammatory effect and is superior to ursolic acid.
[0066] 8. Effect of unsaturated alginate trisaccharide ursolic acid ester (△MU) on chronic eczema mouse model
[0067] 40 male Kunming mice weighing 20-25g were randomly divided into four groups, one as a blank control group, one as a model group, one as a positive control group (ursolic acid group), and one as a △MU group. After the animals were depilated, DNCB (skin test) acetone solution was used to establish the model. After the model was successfully established, the drug-administered group was given 2 times a day, 0.5mL each time (containing ursolic acid or △MU 0.5g). The mice were killed on the 14th day of treatment, and the back skin was taken. The thickness of the skin was measured with a vernier caliper to indicate the degree of skin swelling, the skin tissue was sliced, and the condition of dermal inflammatory cells was observed under an optical microscope. The experimental results are shown in Tables 1 and 2.
[0068] Table 1 Comparison of △MU on the swelling of experimental animals' skin
[0069] Group n Skin swelling (mm) Blank Group 8 0.51±0.011 Model Group 8 1.21±0.075 Ursolic acid group 8 0.74±0.042* △MU group 8 0.62±0.033**
[0070] Note: ** indicates P<0.01 compared with the model group, * indicates P<0.05 compared with the model group.
[0071] Table 2 Comparison of △MU on the number of inflammatory cells in the dermis of experimental animals
[0072] Group n <![CDATA[True dermal inflammatory cell count (cells.(35m 2 ) -1 )]]> Blank Group 8 none Model Group 8 <![CDATA[37±3.4 * ]]> Ursolic acid group 8 <![CDATA[15±1.8 * ]]> △MU group 8 <![CDATA[9±0.7 ** ]]>
[0073] Note: ** indicates P<0.01 compared with the model group, * indicates P<0.05 compared with the model group.
[0074] As shown in Tables 1 and 2, △MU can effectively reduce the swelling of experimental chronic eczema skin and the number of inflammatory cells in the dermis of experimental animals. The △MU group is better than the ursolic acid group.
[0075] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. An unsaturated alginate trisaccharide ursolic acid ester, characterized in that: Its structural formula is as follows: Among them, R1, R2, R3, R4, R5, R6 are C 30 H 47 O2 or H, and at least one of them is C 30 H 47 O2.
2. A method for preparing the unsaturated alginate trisaccharide ursolic acid ester according to claim 1, characterized in that: Take unsaturated alginate trisaccharide and dissolve it in N,N-dimethylformamide, add N,N'-carbonyldiimidazole and 4-dimethylaminopyridine in sequence, and stir at room temperature under nitrogen protection; then add ursolic acid and continue to react at room temperature. After the reaction is completed, reduce pressure and concentrate to remove the solvent, add water to dissolve, extract with dichloromethane, concentrate the aqueous phase and freeze-dry to obtain unsaturated alginate trisaccharide ursolic acid ester.
3. The method for preparing unsaturated alginate trisaccharide ursolic acid ester according to claim 2, characterized in that: The unsaturated alginate trisaccharide is an alginate oligosaccharide with a polymerization degree of 3, and is obtained by connecting unsaturated mannuronic acid, mannuronic acid and guluronic acid in a 1-4 manner.
4. The method for preparing the unsaturated alginate trisaccharide ursolic acid ester according to claim 2 or 3, characterized in that: The preparation method of the unsaturated alginate trisaccharide is as follows: Weigh 20g of sodium alginate and dissolve it in deionized water to make the gel solution concentration 2%, mechanically stir it to make it a uniform system, add alginate lyase, the mass concentration of alginate lyase in sodium alginate is 0.5%, and enzymolysis is carried out at 45℃ for 24h; after the enzymolysis is completed, heat to 100℃, react for 10min, centrifuge, concentrate and freeze-dry the enzymolysis solution to obtain unsaturated alginate oligosaccharides; Unsaturated alginate oligosaccharides were purified using Bio-gel P4 gel column with 0.5M NH4HCO3 as eluent. The effluent was automatically collected, 0.5 mL per tube, and the degree of polymerization of oligosaccharides was determined by ESI-MS. The unsaturated alginate oligosaccharides with a degree of polymerization of 3 were desalted and freeze-dried to obtain unsaturated alginate trisaccharides.
5. The method for preparing unsaturated alginate trisaccharide ursolic acid ester according to claim 2, characterized in that: The preparation method of unsaturated alginate trisaccharide ursolic acid ester is as follows: 2 g of unsaturated alginate trisaccharide is dissolved in 10-40 mL of N,N-dimethylformamide, 2-4 g of N,N'-carbonyldiimidazole and 0.5-2.1 g of 4-dimethylaminopyridine are added in sequence, and stirred at room temperature for 20-70 min under nitrogen protection; 1-3.5 g of ursolic acid is added, and the reaction is continued at room temperature for 4-15 h. After the reaction is completed, the solvent is removed by concentration under reduced pressure, 30-100 mL of water is added to dissolve, and then extracted with 30-60 mL of dichloromethane, and the process is repeated 2-5 times; the aqueous phase is concentrated and freeze-dried to obtain unsaturated alginate trisaccharide ursolic acid ester.
6. The method for preparing unsaturated alginate trisaccharide ursolic acid ester according to claim 5, characterized in that: The degree of substitution of ursolic acid is 5-25%.
7. Use of the unsaturated alginate trisaccharide ursolic acid ester as claimed in claim 1 in the preparation of medical dressings or skin care products for preventing and relieving skin eczema.
8. The use according to claim 7, characterized in that: The unsaturated alginate trisaccharide ursolic acid ester is added as an active ingredient in the preparation of medical dressings or skin care products for preventing and relieving skin eczema in a mass fraction of 0.5-5%.
